Stockchase Opinions

Scott Morrison VSM MedTech Ltd. VSM-T TRADE Jan 14, 2005

Have had a lot of trouble. Lost their CEO. Have to do more research with management before investing. Have some interesting technology. Starting to look interesting.
$1.040

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TRADE
The bane of his existence. Comes back to haunt him. Has not got this one right at all.
DON'T BUY
A tough one because the company is struggling with a management team that is being paid too much. Not doing well from a sales point of view and one of their competitors is starting to give away products as a bundling package.
PAST TOP PICK
(A Top Pick Nov 19/03. Down 83%.) Stock did very well for a whle, but the company was not able to make a viable business. Sold off a long time ago.
DON'T BUY
Has very good technology, but unfortunately it is still in the early stages of being rolled out to the medical community. In the bottom 15% of his database. Earnings estimates have been shaved by about 5% in the last 90 days and 20% in the last 60 days. Most recent quarter had a negative earnings surprise. Expected to lose $0.23 in ’06 and $0.15 in ’07.
DON'T BUY
It is interesting technology. The company is suffering. Give it a pass. He has owned in the past.
DON'T BUY
Ranks in the bottom 1% of his database. Earnings estimates have been revised downwards 12% in the last 90 days.
SELL
Ranks near the bottom. Earnings have been shaved by 23%. Recent financing was very dilutive.
DON'T BUY
Recently entered into a financing agreement. Cash strapped. Existing shareholders tend to get totally diluted of their positions.
DON'T BUY

Likes this. Core business is selling broadcast equipment to cable and telcos. Have done a great job of creating shareholder value by selling off non-core assets such as wireless spectrum and real estate in Saskatchewan. Thinks they are kind of getting to the end of the line and he has sold his position.